8.55
Seres Therapeutics Inc stock is traded at $8.55, with a volume of 83,048.
It is down -7.37% in the last 24 hours and down -33.20% over the past month.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
See More
Previous Close:
$9.23
Open:
$9.1
24h Volume:
83,048
Relative Volume:
1.22
Market Cap:
$81.95M
Revenue:
$123.24M
Net Income/Loss:
$136.00K
P/E Ratio:
-427.50
EPS:
-0.02
Net Cash Flow:
$-148.99M
1W Performance:
-9.04%
1M Performance:
-33.20%
6M Performance:
-43.39%
1Y Performance:
-64.08%
Seres Therapeutics Inc Stock (MCRB) Company Profile
Name
Seres Therapeutics Inc
Sector
Industry
Phone
617 945 9626
Address
200 SIDNEY STREET, CAMBRIDGE, MA
Compare MCRB with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
MCRB
Seres Therapeutics Inc
|
8.55 | 81.95M | 123.24M | 136.00K | -148.99M | -0.02 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
450.03 | 129.44B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
558.52 | 61.42B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ARGX
Argen X Se Adr
|
615.11 | 38.44B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
269.81 | 33.29B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ONC
Beigene Ltd Adr
|
241.75 | 26.95B | 3.81B | -644.79M | -669.77M | -6.24 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-24-24 | Downgrade | JP Morgan | Neutral → Underweight |
Jun-26-23 | Resumed | Oppenheimer | Outperform |
Apr-21-23 | Initiated | JP Morgan | Neutral |
Jul-23-21 | Downgrade | Goldman | Neutral → Sell |
May-18-21 | Resumed | Goldman | Neutral |
Mar-05-21 | Upgrade | Chardan Capital Markets | Neutral → Buy |
Sep-18-20 | Downgrade | Chardan Capital Markets | Buy → Neutral |
Aug-18-20 | Initiated | Piper Sandler | Overweight |
Aug-11-20 | Reiterated | H.C. Wainwright | Buy |
Aug-11-20 | Upgrade | Jefferies | Hold → Buy |
Apr-30-19 | Initiated | Jefferies | Hold |
Oct-22-18 | Initiated | Chardan Capital Markets | Buy |
Oct-13-17 | Initiated | Oppenheimer | Outperform |
Aug-04-17 | Reiterated | H.C. Wainwright | Buy |
Feb-01-17 | Reiterated | FBR & Co. | Outperform |
Aug-12-16 | Reiterated | FBR Capital | Outperform |
Aug-01-16 | Downgrade | BofA/Merrill | Buy → Neutral |
Aug-01-16 | Reiterated | H.C. Wainwright | Buy |
Jul-29-16 | Resumed | H.C. Wainwright | Buy |
Mar-30-16 | Initiated | FBR Capital | Outperform |
Mar-03-16 | Initiated | Guggenheim | Buy |
Jan-25-16 | Initiated | H.C. Wainwright | Buy |
Oct-22-15 | Upgrade | BofA/Merrill | Neutral → Buy |
Jul-22-15 | Initiated | Canaccord Genuity | Buy |
Jul-21-15 | Initiated | Goldman | Neutral |
Jul-21-15 | Initiated | Leerink Partners | Outperform |
View All
Seres Therapeutics Inc Stock (MCRB) Latest News
Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025 - The Globe and Mail
Analysts Set Seres Therapeutics, Inc. (NASDAQ:MCRB) PT at $80.00 - Defense World
Seres Therapeutics Inc expected to post a loss of 54 cents a shareEarnings Preview - TradingView
Seres Therapeutics (NASDAQ:MCRB) Cut to Sell at StockNews.com - Defense World
Seres Therapeutics Reveals Game-Changing Biomarkers for IBD Treatment, Seeks Development Partners - Stock Titan
Seres Therapeutics (MCRB) to Unveil New Findings at 2025 Digesti - GuruFocus
Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases - The Manila Times
Investor’s Delight: Seres Therapeutics Inc (MCRB) Closes Weak at 0.70, Down -2.90 - DWinneX
Press Release Distribution & PR Platform - ACCESS Newswire
Seres Therapeutics (NASDAQ:MCRB) Raised to Hold at StockNews.com - Defense World
MCRB Stock Update: Seres Therapeutics Inc’s Banking’s Market Struggles and Potential Opportunities - investchronicle.com
Seres Therapeutics Inc (MCRB) expanding its growth trajectory ahead - Sete News
Seres Therapeutics Reveals Q1 2025 Results: Live Biotherapeutics Pioneer Updates Growth Strategy - Stock Titan
Seres Therapeutics enacts 1-for-20 reverse stock split By Investing.com - Investing.com India
Seres Therapeutics enacts 1-for-20 reverse stock split - Investing.com
JP Morgan downgrades Seres Therapeutics Inc (MCRB) rating to an Underweight - knoxdaily.com
Oppenheimer Adjusts Seres Therapeutics Price Target to $5 From $9, Maintains Outperform Rating - marketscreener.com
Nestlé Health Science agrees to acquire global rights to VOWST®, product it launched in June 2023 - marketscreener.com
Upcoming Stock Splits This Week (April 21 to April 25) – Stay Invested - The Globe and Mail
Down -48.7% in 4 Weeks, Here's Why Seres Therapeutics (MCRB) Looks Ripe for a Turnaround - NewsBreak: Local News & Alerts
MCRB stock touches 52-week low at $0.46 amid market challenges By Investing.com - Investing.com South Africa
MCRB stock touches 52-week low at $0.46 amid market challenges - Investing.com
Seres Therapeutics enacts stock incentive plan and reverse split By Investing.com - Investing.com South Africa
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Seres Therapeutics enacts stock incentive plan and reverse split - Investing.com
Seres Therapeutics Approves Reverse Stock Split Plan - TipRanks
Seres Therapeutics (NASDAQ:MCRB) Rating Lowered to Sell at StockNews.com - Defense World
Seres Therapeutics Inc (NASDAQ: MCRB): Blank Check On Growth? - stocksregister.com
Analysts Set Seres Therapeutics, Inc. (NASDAQ:MCRB) Price Target at $4.00 - Defense World
Strategic Power Move: Kymera Lands M&A Expert to Accelerate Drug Development Deals - Stock Titan
MCRB stock touches 52-week low at $0.54 amid market challenges - Investing.com Australia
MCRB stock touches 52-week low at $0.54 amid market challenges By Investing.com - Investing.com South Africa
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Regarding Possible Violations of Federal Securities Laws by Certain Officers and Directors of Seres Therapeutics, Inc.MCRB - ACCESS Newswire
5 Best Microbiome Companies (May 2025) - Securities.io
Charles Schwab Investment Management Inc. Purchases 117,107 Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) - Defense World
FY2025 Earnings Forecast for MCRB Issued By Chardan Capital - Defense World
Avantax Advisory Services Inc. Increases Stake in Seres Therapeutics, Inc. (NASDAQ:MCRB) - Defense World
Seres Therapeutics (NASDAQ:MCRB) Given "Buy" Rating at Chardan Capital - MarketBeat
Chardan Capital Reiterates Buy Rating for Seres Therapeutics (NASDAQ:MCRB) - Defense World
Microbiome Disease Pipeline Insight 2025: Over 180 Drugs in Development Across 140+ Companies - GlobeNewswire Inc.
Petri Dish: Flagship spinout Ampersand raises $65M, Seres medical chief lands new role - The Business Journals
Seres Therapeutics, Inc. (NASDAQ:MCRB) Receives $4.00 Consensus Target Price from Brokerages - Defense World
The Goldman Sachs Group Issues Pessimistic Forecast for Seres Therapeutics (NASDAQ:MCRB) Stock Price - Defense World
Seres Therapeutics Inc Stock (MCRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):